Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time t...

Descripción completa

Detalles Bibliográficos
Autores: RUIZ BAÑOBRE, JUAN, Areses Manrique, María Carmen, Mosquera-Martinez, J., Cortegoso Mosquera, Alexandra Sabela, Afonso-Afonso, F. J., DE DIOS ALVAREZ, NOEMI, Fernández Nuñez, Natalia, AZPITARTE RAPOSEIRAS, CRISTINA, Amenedo, M., Santome, L., Firvida Perez, Jose Luis, García Campelo, María del Rosario, García González, Jorge José, Casal Rubio, Joaquín, Vázquez Estévez, Sergio
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/15728
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976357/pdf/tlcr-08-06-1078.pdf
https://www.ncbi.nlm.nih.gov/pubmed/32010585
http://hdl.handle.net/20.500.11940/15728
Access Level:acceso abierto
Palabra clave:CHUF
CHUAC
CHUS
CHUO
CHUVI
HULA
CHUP
IDIS
Descripción
Sumario:The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12-4.60; P<0.0001] and multivariate (HR =3.67, 95% CI, 1.96-6.86; P<0.0001) analyses. Worse LIPI was associated with shorter PFS (HR =1.45, 95% CI, 1.05-2.03; P=0.03), but this correlation did not reach statistical significance in multivariate analysis (HR =1.49, 95% CI, 0.94-2.38; P=0.09). Worse LIPI was associated with lower DCR in univariate [odds ratio (OR) =0.41, 95% CI, 0.24-0.70; P=0.001] and multivariate (OR =0.44, 95% CI, 0.25-0.78; P=0.005) analyses. This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond.

Similares en LA Referencia